Mir Siddiqi
About Mir Siddiqi
Mir Siddiqi is a Scientist specializing in Immuno-Oncology at Bristol-Myers Squibb in Princeton, NJ, with extensive experience in research and clinical roles.
Professional Title and Current Role
Mir Siddiqi is a Scientist currently employed at Bristol-Myers Squibb in Princeton, NJ. Since starting in January 2018, Siddiqi has taken on significant responsibilities in the field of Immuno-Oncology, focusing on Tumor and Tissue Processing.
Education and Academic Background
Mir Siddiqi holds a Master’s degree in Biomedical Sciences from the Rowan University Graduate School of Biomedical Sciences, obtained in 2017. Prior to this, Siddiqi completed a Bachelor of Arts in Cell Biology and Neuroscience with Honors in Psychology at Rutgers University-New Brunswick in 2015. Siddiqi also completed high school at South Brunswick High School in 2011.
Previous Work Experience
Before joining Bristol-Myers Squibb, Mir Siddiqi gained experience in various roles. Siddiqi worked as a Graduate Intern at Celgene in 2017, Research Assistant at Rowan University School of Osteopathic Medicine from 2016 to 2017, and Medical Assistant at Allercare in 2015. Additional roles included Research Assistant at Rutgers University from 2014 to 2015, Clinical Research Associate at Brandywine Hospital from 2014 to 2017, and Premedical Intern at The Bayonne Clinic from 2011 to 2013.
Specializations and Technical Skills
Mir Siddiqi specializes in Immuno-Oncology, with a focus on Tumor and Tissue Processing. Siddiqi is experienced in a variety of technical skills including PBMC Processing, Cell Count, Flow Cytometry, ELISA, and PCR techniques. These skills are pivotal in ensuring the validity and accuracy of scientific research and clinical trials.
Risk Evaluation and Mitigation Strategies (REMS)
As part of the Bristol-Myers Squibb team, Mir Siddiqi works on developing and managing Risk Evaluation and Mitigation Strategies (REMS) to ensure patient safety. This includes managing REMS for medications like Lenalidomide, Pomalyst, and Thalomid, and ensuring other companies using Bristol-Myers Squibb products in clinical testing implement necessary safety safeguards.
Patient Support and Advocacy
Mir Siddiqi is actively involved in initiatives to improve access to care and advocate for health equity. Siddiqi supports programs that offer free medication to eligible, uninsured patients and provides resources to help patients understand their insurance coverage and out-of-pocket costs for medications. Such efforts are aimed at ensuring that medications are used safely and effectively under commercial conditions.